Buc-ee's first Virginia store is here
Why it matters: It's the first of three planned Virginia locations for the massive, and beloved, Texas-based gas station chain.
State of play: Our first Buc-ee's has 120 fuel pumps and 74,000 square feet of roadside convenience store offerings, open 24/7.
But Buc-ee's, as anyone who's been to one knows, is more than a simple roadtrip pitstop.
Those square feet are chock-full of treats like Beaver Nuggets, Texas barbecue, homemade fudge, kolaches, jalapeño peanut brittle and a whole wall of jerky.
Then there are the award-winning bathrooms.
The bottom line: In the words of our colleague Adam Tamburin in Nashville, Buc-ee's turns a roadside pitstop into "a visit to Willy Wonka's factory."
What we're watching: Virginia's next two Buc-ee's outposts are in the works in New Kent off I-64 near exit 211 and in Stafford, off I-95.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Tyler Technologies to Participate in August and September Investor Conferences
PLANO, Texas, July 22, 2025--(BUSINESS WIRE)--Tyler Technologies, Inc. (NYSE: TYL) will participate in four investor conferences in August and September 2025. Conference Date Time and Place Participant(s) Northcoast Research Virtual Summer Management Forum Aug. 5 1x1 meetings by appointment Robert Goulding, vice president, strategic finance and investor relations Hala Elsherbini, senior director, investor relations Oppenheimer Annual Technology, Internet & Communications Virtual Conference Aug. 13 2:55 p.m. ET fireside chat + 1x1 meetings by appointment Brian Miller, executive vice president and chief financial officer Truist Technology Conference Sept. 4 AI Industry-Specific Use Cases Panel + 1x1 meetings by appointment Lotte New York Palace New York City, N.Y. Russell Gainford, chief technology officer Franklin Williams, president, Data & Insights Division, deputy chief technology officer Robert Goulding Goldman Sachs Communacopia + Technology Conference Sept. 10 10:50 a.m. PT fireside chat + 1x1 meetings by appointment Palace Hotel, San Francisco, Calif. Jeff Puckett, chief operating officer Robert Goulding Live webcasts of the fireside chats at Oppenheimer and Goldman Sachs will be accessible at: About Tyler Technologies, Inc. Tyler Technologies (NYSE: TYL) is a leading provider of integrated software and technology services for the public sector. Tyler's end-to-end solutions empower local, state, and federal government entities to operate efficiently and transparently with residents and each other. By connecting data and processes across disparate systems, Tyler's solutions transform how clients turn actionable insights into opportunities and solutions for their communities. Tyler has more than 45,000 successful installations across 13,000 locations, with clients in all 50 states, Canada, the Caribbean, Australia, and other international locations. Tyler has been recognized numerous times for growth and innovation, including on Government Technology's GovTech 100 list. More information about Tyler Technologies, an S&P 500 company headquartered in Plano, Texas, can be found at #TYL_Financial View source version on Contacts Hala ElsherbiniSenior Director, Investor RelationsTyler Technologies, Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Caterpillar Inc. to Announce Second-Quarter 2025 Financial Results Aug. 5
IRVING, Texas, July 22, 2025 /PRNewswire/ -- Caterpillar Inc. (NYSE: CAT) will release second-quarter 2025 financial results at 5:30 a.m. CDT Tuesday, Aug. 5. The full text of the release will be available at and on PR Newswire. The release will be furnished to the U.S. Securities and Exchange Commission (SEC) via a Current Report on Form 8-K in compliance with applicable SEC rules. Teleconference and webcast access:A real-time, listen-only teleconference and webcast of the quarterly results call that Caterpillar conducts with securities analysts and institutional investors will begin at 7:30 a.m. CDT Tuesday, Aug. 5. Supporting materials will be available before the webcast at In addition to the webcast, the one-hour conference call can also be accessed by telephone from both domestic and international locations, with a conference ID provided below: Conference ID: 8390933 Participant Toll-Free Dial-In Number: (800) 715-9871 Participant Toll Dial-In Number: +1 (646) 307-1963 The call can be accessed in real-time at Listeners should go to the website before the live event to download and install any necessary audio software. The transcript from the conference call will be available at following the webcast. For those unable to participate in the live broadcast, the replay will be available at shortly after the live event. There is no charge to access the webcast. A telephone replay will not be available. About CaterpillarWith 2024 sales and revenues of $64.8 billion, Caterpillar Inc. is the world's leading manufacturer of construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines and diesel-electric locomotives. For nearly 100 years, we've been helping customers build a better, more sustainable world and are committed and contributing to a reduced-carbon future. Our innovative products and services, backed by our global dealer network, provide exceptional value that helps customers succeed. Caterpillar does business on every continent, principally operating through three primary segments – Construction Industries, Resource Industries and Energy & Transportation – and providing financing and related services through our Financial Products segment. Visit us at or join the conversation on our social media channels at Caterpillar's latest financial results are also available online: (live broadcast/replays of quarterly conference call) View original content to download multimedia: SOURCE Caterpillar Inc. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
26 minutes ago
- Yahoo
Moleculin Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
– Video webcast now available on-demand HOUSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ('Moleculin' or the 'Company'), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that Walter Klemp, Founder, President, CEO and Chairman of Moleculin, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. As part of the segment, Mr. Klemp dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development. The on-demand video webcast is now available on as well as the Events page of the Investors section of the Company's website ( About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications. For more information about the Company, please visit and connect on X, LinkedIn and Facebook. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775MBRX@ in to access your portfolio
